The Use of Chimeric Antigen Receptor to Control HIV Infection | Office of Technology Transfer, NIH

The Use of Chimeric Antigen Receptor to Control HIV Infection | Office of Technology Transfer, NIH

 Drug Development Opportunity:

Novel Treatment for HIV Infection

HIV-infected T cell. Scanning electron micrograph of an HIV-infected T cell. Credit: NIAID



Scientists at the NIAID Laboratory of Viral Diseases have developed nucleic acids that encode novel chimeric antigen receptor (CAR) proteins. When the CARs are expressed on host T cells (CAR T cells), they can be used to specifically kill HIV-infected cells within HIV-infected individuals. This technology can also be used to protect uninfected cells within HIV-infected individuals by rendering them resistant to infection by HIV. There is a growing body of in vitro and in vivo data that provides support for the continued development of NIAID’s CAR T-cells as a treatment—and potential cure—for HIV infection. Read more about this exciting collaboration/licensing opportunity at https://www.ott.nih.gov/technology/e-089-2002.